We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+37.81%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$4.66B
AUM Growth
+$539M
Cap. Flow
-$225M
Cap. Flow %
-4.83%
Top 10 Hldgs %
41.2%
Holding
160
New
26
Increased
26
Reduced
23
Closed
30

Top Buys

Rank Stock Value
1
SEER icon
Seer Inc
SEER
+$372M
2
KRON
Kronos Bio
KRON
+$41.3M
3
SQZ
SQZ Biotechnologies Company
SQZ
+$41M
4
Z icon
Zillow
Z
+$38.7M
5
CCXI
ChemoCentryx, Inc.
CCXI
+$37.2M

Top Sells

Rank Stock Value
1
BNTX icon
BioNTech
BNTX
+$71.8M
2
BABA icon
Alibaba
BABA
+$62.5M
3
MRNA icon
Moderna
MRNA
+$25.3M
4
STNE icon
StoneCo
STNE
+$21.2M
5
SRRK icon
Scholar Rock
SRRK
+$14.3M

Sector Composition

Rank Sector Weight
1 Healthcare 77.21%
2 Consumer Discretionary 9.12%
3 Technology 2.01%
4 Communication Services 1.85%
5 Real Estate 1.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NG icon
51
NovaGold Resources
NG
$2.6B
$25.1M 0.54%
2,600,000
– –
FOLD
52
CALL
DELISTED
Amicus Therapeutics
FOLD
$23.1M 0.5%
1,000,000
– –
GOSS icon
53
Gossamer Bio
GOSS
$100M
$22.8M 0.49%
2,358,968
– –
TBIO
54
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$22.1M 0.47%
1,200,000
-200,000
-14% -$3.58M
AGEN
55
Agenus
AGEN
$282M
$21.9M 0.47%
351,555
– –
SLB icon
56
CALL
SLB Ltd
SLB
$73.4B
$21.8M 0.47%
+1,000,000
New +$18.9M
BBIO icon
57
BridgeBio Pharma
BBIO
$16.5B
$21.3M 0.46%
300,000
-100,000
-25% -$4.82M
KURA icon
58
Kura Oncology
KURA
$819M
$19.6M 0.42%
600,000
+50,900
+9% +$1.79M
RPTX
59
DELISTED
Repare Therapeutics
RPTX
$19.6M 0.42%
570,000
– –
TECH icon
60
Bio-Techne
TECH
$11.2B
$19.1M 0.41%
240,000
– –
IOVA icon
61
Iovance Biotherapeutics
IOVA
$2.08B
$18.6M 0.4%
400,000
– –
FMTX
62
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$17.4M 0.37%
+500,000
New +$21.8M
TCOM icon
63
Trip.com Group
TCOM
$29.1B
$16.9M 0.36%
500,000
-70,000
-12% -$2.28M
RLAY icon
64
Relay Therapeutics
RLAY
$4.09B
$16.6M 0.36%
400,000
– –
ZYME icon
65
Zymeworks
ZYME
$1.64B
$16.5M 0.36%
+350,000
New +$16.3M
NBTX
66
Nanobiotix
NBTX
$1.94B
$16.5M 0.35%
+1,000,000
New +$17.2M
CRDF icon
67
Cardiff Oncology
CRDF
$62.8M
$16.2M 0.35%
900,000
– –
KYMR icon
68
Kymera Therapeutics
KYMR
$8.78B
$15.5M 0.33%
250,000
– –
STOK icon
69
Stoke Therapeutics
STOK
$1.86B
$15.5M 0.33%
250,000
-20,750
-8% -$951K
TCRR
70
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$15.5M 0.33%
500,000
– –
IQ icon
71
iQIYI
IQ
$1.22B
$14.9M 0.32%
+850,000
New +$19.2M
KYNB
72
Kyntra Bio
KYNB
$27.9M
$14.8M 0.32%
16,000
+800
+5% +$841K
CRIS icon
73
Curis
CRIS
$9.74M
$14.8M 0.32%
4,512
+1,000
+28% +$1.2M
BLU
74
DELISTED
BELLUS Health Inc.
BLU
$14.5M 0.31%
4,750,000
+4,275,000
+900% +$11.6M
KRYS icon
75
Krystal Biotech
KRYS
$10.8B
$14.3M 0.31%
237,500
– –
1 2
3
4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q4 2020 Portfolio in Review

As of Q4 2020, Artal Group held 160 positions worth $4.66B, up 13% from $4.12B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Artal Group withdrew a net $225M in Q4 2020, closing 30 positions and reducing 23 holdings. Its most notable exit was StoneCo, an estimated $21.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 57% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, Artal Group opened a new position in Seer Inc worth $328M.

  • Artal Group's largest Q4 2020 buy was Seer Inc: 5,840,911 shares worth $328M.
  • Artal Group added most to Zillow in Q4 2020, an estimated $38.7M increase.
  • Artal Group's biggest Q4 2020 reduction was BioNTech, cutting an estimated $71.8M.
  • Artal Group fully exited StoneCo in Q4 2020, selling an estimated $21.2M.
  • Artal Group's ten largest holdings make up 41% of its $4.66B portfolio in Q4 2020.
  • Artal Group opened 26 new positions and closed 30 in Q4 2020.
  • Artal Group's portfolio value rose 13% quarter-over-quarter to $4.66B.

Based on Artal Group's 13F filing for Q4 2020, filed 11 Feb 2021.